atezolizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5151 1380723-44-3

Description:

MoleculeDescription

Synonyms:

  • atezolizumab
  • tecentriq
  • RG7446
  • MPDL3280A
A monoclonal antibody that targets programmed death-ligand 1 (CD274 ANTIGEN) and is used to treat urothelial carcinoma, the most common type of bladder cancer.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 18, 2016 FDA GENENTECH INC
Jan. 19, 2018 PMDA Chugai Pharmaceutical Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonitis 273.09 25.78 142 13784 29368 50561830
Neutrophil count decreased 261.80 25.78 161 13765 45865 50545333
Febrile neutropenia 260.22 25.78 215 13711 97452 50493746
Hypothyroidism 216.27 25.78 128 13798 33997 50557201
Death 201.42 25.78 337 13589 325042 50266156
Anaemia 191.31 25.78 287 13639 252169 50339029
Pyrexia 180.68 25.78 351 13575 379852 50211346
Colitis 167.75 25.78 114 13812 38415 50552783
Hyperthyroidism 155.47 25.78 73 13853 12102 50579096
Immune-mediated hepatitis 143.39 25.78 36 13890 868 50590330
Interstitial lung disease 130.92 25.78 112 13814 53064 50538134
Intentional product use issue 127.56 25.78 130 13796 76788 50514410
Neutropenic sepsis 122.01 25.78 65 13861 14082 50577116
Disease progression 118.83 25.78 139 13787 95727 50495471
Drug ineffective 114.11 25.78 42 13884 819291 49771907
Myocarditis 102.52 25.78 48 13878 7899 50583299
Hypokalaemia 99.84 25.78 122 13804 87870 50503328
Encephalitis 96.52 25.78 45 13881 7335 50583863
Platelet count decreased 92.85 25.78 126 13800 100600 50490598
Thrombocytopenia 90.47 25.78 141 13785 127532 50463666
Skin candida 89.60 25.78 27 13899 1299 50589899
Systemic immune activation 89.05 25.78 16 13910 66 50591132
Immune-mediated enterocolitis 86.59 25.78 25 13901 1035 50590163
Adrenal insufficiency 81.30 25.78 50 13876 14193 50577005
Hepatic function abnormal 78.68 25.78 68 13858 32613 50558585
Mucosal inflammation 76.03 25.78 73 13853 40069 50551129
Pain 68.83 25.78 37 13889 578866 50012332
Neutropenia 65.45 25.78 133 13793 147832 50443366
Hyperglycaemia 59.31 25.78 61 13865 36344 50554854
Type 1 diabetes mellitus 56.86 25.78 24 13902 3089 50588109
Cytokine release syndrome 56.24 25.78 33 13893 8601 50582597
Immune-mediated encephalitis 55.27 25.78 11 13915 86 50591112
Embolism 54.45 25.78 30 13896 6938 50584260
Lymphocyte count decreased 53.93 25.78 50 13876 26257 50564941
Joint swelling 52.34 25.78 4 13922 245282 50345916
Encephalopathy 52.24 25.78 55 13871 33656 50557542
Hepatitis 51.77 25.78 53 13873 31400 50559798
Hypomagnesaemia 51.36 25.78 46 13880 23110 50568088
Enterocolitis 50.56 25.78 28 13898 6539 50584659
Rash maculo-papular 49.59 25.78 48 13878 26593 50564605
Aspartate aminotransferase increased 48.17 25.78 81 13845 77917 50513281
Sepsis 47.88 25.78 110 13816 132815 50458383
Abdominal discomfort 46.14 25.78 5 13921 231636 50359562
Metastases to central nervous system 45.79 25.78 32 13894 11250 50579948
Tubulointerstitial nephritis 45.69 25.78 36 13890 15175 50576023
Drug hypersensitivity 43.96 25.78 8 13918 251002 50340196
Drug-induced liver injury 43.82 25.78 46 13880 28049 50563149
Swelling 43.64 25.78 3 13923 200869 50390329
Hepatic failure 41.91 25.78 48 13878 32235 50558963
Autoimmune hepatitis 41.90 25.78 26 13900 7493 50583705
Encephalitis autoimmune 41.89 25.78 15 13911 1243 50589955
Alanine aminotransferase increased 40.90 25.78 81 13845 88278 50502920
Constipation 40.84 25.78 128 13798 185580 50405618
Thyroiditis 39.92 25.78 16 13910 1806 50589392
Small intestinal obstruction 39.81 25.78 34 13892 16034 50575164
Acute kidney injury 38.59 25.78 144 13782 227914 50363284
Myasthenia gravis 38.37 25.78 19 13907 3533 50587665
Myositis 38.19 25.78 25 13901 7895 50583303
Drug interaction 38.04 25.78 5 13921 199616 50391582
Nephritis 38.00 25.78 16 13910 2046 50589152
Pancytopenia 37.65 25.78 76 13850 83954 50507244
Nervous system disorder 37.51 25.78 33 13893 16190 50575008
Peripheral sensory neuropathy 37.25 25.78 23 13903 6568 50584630
White blood cell count decreased 37.06 25.78 92 13834 116630 50474568
Autoimmune haemolytic anaemia 36.24 25.78 19 13907 3980 50587218
Metastases to meninges 35.12 25.78 15 13911 1987 50589211
Ascites 34.72 25.78 46 13880 35815 50555383
Dehydration 34.35 25.78 106 13820 152343 50438855
Adrenocorticotropic hormone deficiency 34.32 25.78 9 13917 259 50590939
Rheumatoid arthritis 34.30 25.78 7 13919 202543 50388655
Weight increased 34.14 25.78 7 13919 201884 50389314
Meningitis 33.68 25.78 21 13905 6100 50585098
Peripheral swelling 33.09 25.78 8 13918 205928 50385270
General physical health deterioration 32.99 25.78 100 13826 142334 50448864
Proteinuria 32.96 25.78 31 13895 16566 50574632
Hyponatraemia 31.81 25.78 77 13849 96062 50495136
Radiation pneumonitis 30.21 25.78 12 13914 1323 50589875
Sarcoidosis 29.61 25.78 18 13908 4999 50586199
Peripheral motor neuropathy 29.40 25.78 12 13914 1419 50589779
Haemophagocytic lymphohistiocytosis 29.36 25.78 22 13904 8611 50582587
Decreased appetite 29.21 25.78 121 13805 200802 50390396
Toxicity to various agents 29.18 25.78 11 13915 212488 50378710
Transaminases increased 28.97 25.78 37 13889 27787 50563411
Hypoxia 28.80 25.78 51 13875 51072 50540126
Sinusitis 28.65 25.78 6 13920 170552 50420646
Hypophysitis 28.30 25.78 12 13914 1562 50589636
Myelosuppression 28.29 25.78 26 13900 13491 50577707
Diarrhoea 27.34 25.78 264 13662 588212 50002986
Treatment failure 27.31 25.78 3 13923 137634 50453564
Hypopituitarism 27.27 25.78 10 13916 887 50590311
Guillain-Barre syndrome 27.25 25.78 15 13911 3462 50587736
Terminal ileitis 26.99 25.78 9 13917 602 50590596
Female genital tract fistula 26.51 25.78 15 13911 3651 50587547
Nasopharyngitis 26.46 25.78 10 13916 192917 50398281
Maternal exposure during pregnancy 26.07 25.78 6 13920 159772 50431426
Cholangitis 25.93 25.78 16 13910 4563 50586635

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonitis 258.94 19.47 174 16599 27870 29529884
Interstitial lung disease 197.37 19.47 201 16572 57517 29500237
Hypothyroidism 179.46 19.47 112 16661 15794 29541960
Disease progression 167.92 19.47 219 16554 81697 29476057
Hyperthyroidism 157.23 19.47 83 16690 8525 29549229
Myelosuppression 147.84 19.47 90 16683 12137 29545617
Febrile neutropenia 137.79 19.47 236 16537 112004 29445750
Pyrexia 134.72 19.47 412 16361 287210 29270544
Encephalitis 131.79 19.47 67 16706 6363 29551391
Adrenal insufficiency 129.74 19.47 80 16693 11034 29546720
Colitis 123.74 19.47 118 16655 31130 29526624
Hepatic function abnormal 118.47 19.47 128 16645 39131 29518623
Myocarditis 113.20 19.47 73 16700 10883 29546871
Neutrophil count decreased 107.57 19.47 128 16645 43439 29514315
Death 100.73 19.47 421 16352 341663 29216091
Oesophageal varices haemorrhage 95.34 19.47 41 16732 2661 29555093
Cholangitis 95.01 19.47 57 16716 7480 29550274
Autoimmune hepatitis 90.11 19.47 43 16730 3559 29554195
Drug interaction 88.72 19.47 6 16767 197379 29360375
Toxicity to various agents 81.94 19.47 4 16769 173657 29384097
Immune-mediated enterocolitis 81.94 19.47 32 16741 1621 29556133
Tumour haemorrhage 78.87 19.47 35 16738 2450 29555304
Hepatitis 77.55 19.47 76 16697 20707 29537047
Myositis 69.87 19.47 53 16720 10230 29547524
Hyponatraemia 67.29 19.47 130 16643 67503 29490251
Proteinuria 66.96 19.47 62 16711 15742 29542012
Radiation pneumonitis 66.29 19.47 30 16743 2199 29555555
Tumour rupture 62.23 19.47 16 16757 198 29557556
Autoimmune colitis 61.49 19.47 22 16751 871 29556883
Nephritis 54.95 19.47 26 16747 2110 29555644
Aspartate aminotransferase increased 54.80 19.47 111 16662 59614 29498140
Ascites 54.27 19.47 84 16689 36535 29521219
Intentional product use issue 51.49 19.47 89 16684 42409 29515345
Immune-mediated hepatitis 50.05 19.47 22 16751 1505 29556249
Drug ineffective 47.99 19.47 83 16690 363087 29194667
Systemic immune activation 45.82 19.47 9 16764 27 29557727
Pneumonia 45.80 19.47 324 16449 319848 29237906
Immune-mediated lung disease 45.74 19.47 17 16756 751 29557003
Paraneoplastic neurological syndrome 45.10 19.47 9 16764 30 29557724
Erythema multiforme 44.27 19.47 36 16737 7681 29550073
Liver disorder 43.00 19.47 65 16708 27684 29530070
Blood bilirubin increased 42.39 19.47 72 16701 33821 29523933
Metastases to meninges 41.57 19.47 18 16755 1187 29556567
Metastases to central nervous system 40.34 19.47 33 16740 7098 29550656
Alanine aminotransferase increased 40.01 19.47 109 16664 70835 29486919
Anaemia 39.00 19.47 220 16553 200731 29357023
Tubulointerstitial nephritis 38.89 19.47 49 16724 17594 29540160
Hypophysitis 38.83 19.47 20 16753 1950 29555804
Hepatic failure 38.17 19.47 66 16707 31446 29526308
Enterocolitis 38.03 19.47 31 16742 6635 29551119
Immune-mediated encephalitis 36.66 19.47 9 16764 91 29557663
Varices oesophageal 35.06 19.47 22 16751 3124 29554630
Platelet count decreased 34.63 19.47 134 16639 104538 29453216
Fulminant type 1 diabetes mellitus 33.87 19.47 13 16760 628 29557126
Decreased appetite 33.55 19.47 167 16606 145175 29412579
Encephalitis autoimmune 32.68 19.47 12 16761 512 29557242
Tumour pseudoprogression 32.59 19.47 11 16762 365 29557389
Myasthenia gravis 32.54 19.47 21 16752 3130 29554624
Thrombophlebitis migrans 32.40 19.47 8 16765 83 29557671
Type 1 diabetes mellitus 32.11 19.47 22 16751 3622 29554132
General physical health deterioration 30.28 19.47 127 16646 102730 29455024
Depression 29.83 19.47 6 16767 85141 29472613
Drug-induced liver injury 29.75 19.47 48 16725 21607 29536147
Therapy partial responder 29.28 19.47 24 16749 5175 29552579
Meningitis 28.73 19.47 22 16751 4303 29553451
Lung disorder 28.50 19.47 57 16716 30305 29527449
Condition aggravated 28.08 19.47 25 16748 146270 29411484
Serous retinal detachment 27.61 19.47 10 16763 410 29557344
Bleeding varicose vein 27.40 19.47 9 16764 274 29557480
Tumour hyperprogression 27.20 19.47 6 16767 36 29557718
Embolism 27.18 19.47 26 16747 6870 29550884
Hepatic encephalopathy 26.84 19.47 35 16738 13000 29544754
Neutropenic sepsis 26.53 19.47 33 16740 11694 29546060
Peripheral sensory neuropathy 26.51 19.47 24 16749 5915 29551839
Hyperhidrosis 26.13 19.47 3 16770 64537 29493217
Peripheral swelling 25.72 19.47 3 16770 63736 29494018
Guillain-Barre syndrome 25.70 19.47 22 16751 5036 29552718
Haemoglobin decreased 25.37 19.47 15 16758 108360 29449394
Somnolence 24.98 19.47 11 16762 93944 29463810
Tumour thrombosis 24.68 19.47 6 16767 58 29557696
Thrombocytopenia 24.39 19.47 145 16628 134678 29423076
Hypopituitarism 24.20 19.47 14 16759 1716 29556038
Tremor 24.11 19.47 6 16767 73532 29484222
Haemoptysis 23.62 19.47 53 16720 30497 29527257
Acute kidney injury 23.25 19.47 241 16532 265026 29292728
Tumour pain 23.10 19.47 11 16762 905 29556849
Loss of consciousness 22.50 19.47 7 16766 74049 29483705
Gastrointestinal perforation 21.57 19.47 17 16756 3466 29554288
Hepatobiliary disease 21.47 19.47 8 16765 356 29557398
Hypercalcaemia 21.36 19.47 31 16742 12728 29545026
Secondary adrenocortical insufficiency 21.09 19.47 11 16762 1100 29556654
Scleroderma-like reaction 20.99 19.47 5 16768 44 29557710
Dizziness 20.95 19.47 48 16725 189636 29368118
Neutropenia 20.91 19.47 137 16636 131574 29426180
Feeling abnormal 20.91 19.47 3 16770 54442 29503312
Hypokalaemia 20.60 19.47 69 16704 50134 29507620
Myasthenic syndrome 20.60 19.47 8 16765 399 29557355
Subclavian artery occlusion 20.52 19.47 6 16767 123 29557631
Upper gastrointestinal haemorrhage 20.39 19.47 41 16732 21873 29535881
Weight increased 20.34 19.47 9 16764 76658 29481096
Autoimmune haemolytic anaemia 20.09 19.47 17 16756 3831 29553923
Nephrotic syndrome 19.70 19.47 21 16752 6307 29551447

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pneumonitis 467.03 21.22 288 28845 50077 64419522
Hypothyroidism 384.30 21.22 235 28898 40222 64429377
Febrile neutropenia 379.92 21.22 445 28688 187212 64282387
Neutrophil count decreased 347.60 21.22 284 28849 76912 64392687
Interstitial lung disease 325.96 21.22 303 28830 97429 64372170
Pyrexia 288.94 21.22 718 28415 557926 63911673
Hyperthyroidism 288.52 21.22 148 28985 18031 64451568
Colitis 270.64 21.22 219 28914 58455 64411144
Disease progression 226.90 21.22 299 28834 141381 64328218
Encephalitis 210.09 21.22 106 29027 12465 64457134
Anaemia 208.18 21.22 499 28634 378181 64091418
Myocarditis 206.56 21.22 116 29017 16927 64452672
Hepatic function abnormal 200.10 21.22 192 28941 64121 64405478
Adrenal insufficiency 191.65 21.22 122 29011 22365 64447234
Death 179.79 21.22 551 28582 482154 63987445
Immune-mediated hepatitis 167.96 21.22 57 29076 2432 64467167
Drug ineffective 162.91 21.22 89 29044 840158 63629441
Immune-mediated enterocolitis 145.24 21.22 52 29081 2604 64466995
Drug interaction 138.14 21.22 6 29127 362077 64107522
Myelosuppression 136.04 21.22 101 29032 23729 64445870
Platelet count decreased 133.27 21.22 257 28876 167454 64302145
Cholangitis 124.07 21.22 71 29062 10731 64458868
Neutropenic sepsis 122.57 21.22 94 29039 23178 64446421
Systemic immune activation 119.58 21.22 25 29108 146 64469453
Toxicity to various agents 111.32 21.22 16 29117 363497 64106102
Myositis 110.87 21.22 77 29056 16300 64453299
Autoimmune hepatitis 109.75 21.22 64 29069 10020 64459579
Proteinuria 104.11 21.22 92 29041 27631 64441968
Thrombocytopenia 99.82 21.22 273 28860 223528 64246071
Aspartate aminotransferase increased 99.32 21.22 187 28946 119601 64349998
Hypokalaemia 95.77 21.22 186 28947 121717 64347882
Hepatitis 93.38 21.22 109 29024 45473 64424126
Pneumonia 89.45 21.22 492 28641 559084 63910515
Enterocolitis 87.25 21.22 59 29074 11959 64457640
Oesophageal varices haemorrhage 86.27 21.22 39 29094 3590 64466009
Radiation pneumonitis 86.27 21.22 38 29095 3290 64466309
Hyponatraemia 81.67 21.22 196 28937 148143 64321456
Immune-mediated encephalitis 80.98 21.22 20 29113 266 64469333
Tubulointerstitial nephritis 80.79 21.22 84 29049 30825 64438774
Hypophysitis 80.67 21.22 37 29096 3522 64466077
Nephritis 79.82 21.22 37 29096 3609 64465990
Drug hypersensitivity 78.81 21.22 8 29125 237807 64231792
Tumour haemorrhage 78.19 21.22 36 29097 3457 64466142
Type 1 diabetes mellitus 77.83 21.22 42 29091 5663 64463936
Joint swelling 77.59 21.22 5 29128 215377 64254222
Embolism 76.95 21.22 55 29078 12180 64457419
Ascites 75.58 21.22 115 29018 61886 64407713
Product dose omission issue 74.95 21.22 3 29130 194744 64274855
Peripheral swelling 74.91 21.22 5 29128 209148 64260451
Alanine aminotransferase increased 74.71 21.22 182 28951 138849 64330750
Neutropenia 73.86 21.22 257 28876 239367 64230232
Tumour rupture 71.57 21.22 19 29114 342 64469257
Decreased appetite 68.71 21.22 280 28853 281009 64188590
Hepatic failure 67.87 21.22 103 29030 55291 64414308
Autoimmune colitis 67.73 21.22 25 29108 1366 64468233
Skin candida 66.31 21.22 26 29107 1677 64467922
Peripheral sensory neuropathy 64.42 21.22 48 29085 11330 64458269
Immune-mediated lung disease 63.72 21.22 23 29110 1179 64468420
Drug-induced liver injury 63.27 21.22 92 29041 47551 64422048
Meningitis 63.12 21.22 42 29091 8287 64461312
Condition aggravated 62.83 21.22 46 29087 372380 64097219
Myasthenia gravis 61.33 21.22 36 29097 5702 64463897
General physical health deterioration 61.02 21.22 217 28916 204208 64265391
Metastases to meninges 59.86 21.22 28 29105 2787 64466812
Erythema multiforme 58.73 21.22 52 29081 15649 64453950
Metastases to central nervous system 57.95 21.22 49 29084 13863 64455736
Sepsis 57.57 21.22 231 28902 230110 64239489
Weight increased 57.44 21.22 13 29120 213335 64256264
Encephalitis autoimmune 57.01 21.22 24 29109 1860 64467739
Pain 56.94 21.22 102 29031 553409 63916190
Liver disorder 56.77 21.22 93 29040 53258 64416341
Lymphocyte count decreased 56.10 21.22 80 29053 40619 64428980
Abdominal discomfort 55.79 21.22 8 29125 182314 64287285
Acute kidney injury 55.66 21.22 370 28763 448870 64020729
Cytokine release syndrome 55.13 21.22 57 29076 20772 64448827
Blood bilirubin increased 54.19 21.22 95 29038 57458 64412141
Thyroiditis 53.15 21.22 28 29105 3596 64466003
Rash maculo-papular 52.80 21.22 84 29049 46942 64422657
Encephalopathy 52.70 21.22 95 29038 58724 64410875
Autoimmune haemolytic anaemia 51.98 21.22 35 29098 7041 64462558
Hyperglycaemia 51.50 21.22 96 29037 60872 64408727
White blood cell count decreased 49.19 21.22 170 28963 157667 64311932
Hypopituitarism 48.97 21.22 24 29109 2649 64466950
Nasopharyngitis 48.83 21.22 14 29119 196059 64273540
Intentional product use issue 48.20 21.22 122 29011 95242 64374357
Fulminant type 1 diabetes mellitus 47.44 21.22 18 29115 1062 64468537
Swelling 46.82 21.22 8 29125 160210 64309389
Hypomagnesaemia 46.49 21.22 70 29063 37306 64432293
Pleural effusion 45.41 21.22 143 28990 126416 64343183
Tumour hyperprogression 44.56 21.22 11 29122 146 64469453
Paraneoplastic neurological syndrome 43.43 21.22 9 29124 50 64469549
Guillain-Barre syndrome 42.75 21.22 32 29101 7603 64461996
Sinusitis 41.10 21.22 8 29125 145920 64323679
Therapeutic product effect decreased 40.58 21.22 3 29130 115348 64354251
Fall 40.01 21.22 80 29053 416746 64052853
Transaminases increased 39.91 21.22 72 29061 44522 64425077
Diarrhoea 39.72 21.22 499 28634 722205 63747394
Small intestinal obstruction 38.01 21.22 50 29083 23523 64446076
Tumour pain 37.35 21.22 18 29115 1915 64467684
Pericardial effusion 37.21 21.22 65 29068 39189 64430410
Dizziness 36.79 21.22 88 29045 430075 64039524
Constipation 36.66 21.22 202 28931 229135 64240464
Somnolence 35.82 21.22 24 29109 203621 64265978
Mucosal inflammation 35.80 21.22 84 29049 62500 64407099
Tumour pseudoprogression 35.74 21.22 12 29121 495 64469104
Rheumatoid arthritis 35.29 21.22 15 29118 164279 64305320
Hyperhidrosis 34.86 21.22 7 29126 124913 64344686
Therapy partial responder 34.51 21.22 32 29101 10216 64459383
Hepatic encephalopathy 34.46 21.22 45 29088 21021 64448578
Haemophagocytic lymphohistiocytosis 34.21 21.22 41 29092 17568 64452031
Musculoskeletal stiffness 34.18 21.22 7 29126 123199 64346400
Blood pressure increased 33.62 21.22 18 29115 172534 64297065
Adrenocorticotropic hormone deficiency 33.03 21.22 13 29120 847 64468752
Thrombophlebitis migrans 32.99 21.22 10 29123 295 64469304
Contraindicated product administered 32.36 21.22 5 29128 107824 64361775
Serous retinal detachment 31.99 21.22 12 29121 686 64468913
Ileus 31.43 21.22 45 29088 22921 64446678
Therapeutic product effect incomplete 30.60 21.22 5 29128 103477 64366122
Cortisol decreased 30.55 21.22 15 29118 1662 64467937
Haemoptysis 30.45 21.22 68 29065 48980 64420619
Headache 30.11 21.22 130 29003 529337 63940262
Insomnia 30.11 21.22 27 29106 197809 64271790
Varices oesophageal 29.84 21.22 22 29111 5108 64464491
Subacute cutaneous lupus erythematosus 29.78 21.22 18 29115 3007 64466592
Tremor 29.56 21.22 15 29118 148215 64321384
Pneumothorax 29.49 21.22 45 29088 24253 64445346
Neuropathy peripheral 29.42 21.22 118 29015 117407 64352192
Cholangitis sclerosing 28.64 21.22 15 29118 1904 64467695
COVID-19 28.49 21.22 79 29054 65061 64404538
Nervous system disorder 28.38 21.22 43 29090 23035 64446564
Bleeding varicose vein 28.31 21.22 10 29123 481 64469118
Stomatitis 28.20 21.22 111 29022 109494 64360105
Mobility decreased 28.12 21.22 3 29130 85837 64383762
Arthralgia 28.04 21.22 104 29029 442156 64027443
Febrile infection 27.88 21.22 17 29116 2884 64466715
Treatment failure 27.88 21.22 9 29124 116807 64352792
Tumour necrosis 27.35 21.22 14 29119 1695 64467904
Large intestine perforation 27.24 21.22 31 29102 12573 64457026
Muscle spasms 27.05 21.22 15 29118 141008 64328591
Pulmonary embolism 26.87 21.22 134 28999 146222 64323377
Nephrotic syndrome 26.80 21.22 27 29106 9540 64460059
Febrile bone marrow aplasia 26.59 21.22 29 29104 11226 64458373
Gastrointestinal perforation 26.57 21.22 21 29112 5403 64464196
Proctitis 26.55 21.22 17 29116 3142 64466457
Cancer pain 26.45 21.22 19 29114 4238 64465361
Pancytopenia 26.16 21.22 131 29002 143178 64326421
Subileus 25.97 21.22 20 29113 4957 64464642
Hypercalcaemia 25.94 21.22 49 29084 31367 64438232
Secondary adrenocortical insufficiency 25.82 21.22 15 29118 2330 64467269
Respiratory failure 25.75 21.22 142 28991 161041 64308558
Hepatobiliary disease 25.52 21.22 10 29123 644 64468955
Maternal exposure during pregnancy 25.47 21.22 6 29127 95878 64373721
Adrenal disorder 25.14 21.22 13 29120 1607 64467992
Tumour lysis syndrome 25.01 21.22 37 29096 19403 64450196
Peripheral motor neuropathy 25.01 21.22 16 29117 2954 64466645
Lung disorder 24.97 21.22 72 29061 60628 64408971
Disseminated intravascular coagulation 24.92 21.22 49 29084 32299 64437300
Enteritis 24.92 21.22 29 29104 12048 64457551
Tumour inflammation 24.74 21.22 5 29128 24 64469575
Amylase increased 24.72 21.22 26 29107 9659 64459940
Sarcoidosis 24.28 21.22 21 29112 6125 64463474
Loss of consciousness 24.11 21.22 19 29114 148346 64321253
Lipase increased 23.92 21.22 31 29102 14371 64455228
Haemoglobin decreased 23.75 21.22 32 29101 195031 64274568
Immune-mediated hepatic disorder 23.72 21.22 9 29124 531 64469068
Contusion 23.53 21.22 11 29122 113954 64355645
International normalised ratio increased 23.01 21.22 4 29129 79163 64390436
Tumour thrombosis 22.98 21.22 6 29127 101 64469498
Dehydration 22.92 21.22 172 28961 216591 64253008
Blood creatine phosphokinase increased 22.69 21.22 68 29065 58490 64411109
Paraneoplastic dermatomyositis 22.66 21.22 5 29128 39 64469560
Pain in extremity 22.11 21.22 67 29066 303018 64166581
Bradycardia 22.06 21.22 13 29120 118206 64351393
Cholecystitis 21.93 21.22 35 29098 19601 64449998
Limbic encephalitis 21.82 21.22 9 29124 662 64468937
Palpitations 21.70 21.22 10 29123 104478 64365121
Portal vein thrombosis 21.65 21.22 18 29115 4973 64464626
Female genital tract fistula 21.59 21.22 14 29119 2644 64466955
Muscular weakness 21.56 21.22 114 29019 127224 64342375
Hospitalisation 21.43 21.22 4 29129 75203 64394396
Autoimmune myocarditis 21.42 21.22 7 29126 265 64469334

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FF05 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000082082 Immune Checkpoint Inhibitors
FDA CS M0001352 Antibodies
FDA CS M0001357 Antibodies, Monoclonal
FDA CS M0556300 Antibodies, Monoclonal, Humanized
FDA MoA N0000191259 Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC N0000191260 Programmed Death Receptor-1 Blocking Antibody

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Transitional cell carcinoma indication 27090000 DOID:2671
Liver cell carcinoma indication 109841003 DOID:684
Germline BRCA-mutated, HER2-negative metastatic breast cancer indication 767444009
Metastatic non-small cell lung cancer indication 457721000124104
Extensive stage primary small cell carcinoma of lung indication 683991000119103




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Programmed cell death 1 ligand 1 CD molecules ANTIBODY BINDING Kd 9.39 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
52CMI0WC3Y UNII
4035750 VANDF
C4055433 UMLSCUI
CHEMBL3707227 ChEMBL_ID
D10773 KEGG_DRUG
DB11595 DRUGBANK_ID
9814 INN_ID
7990 IUPHAR_LIGAND_ID
1792776 RXNORM
240980 MMSL
31671 MMSL
d08438 MMSL
719371003 SNOMEDCT_US
763505003 SNOMEDCT_US
016856 NDDF
C000594389 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-917 INJECTION, SOLUTION 1200 mg INTRAVENOUS BLA 29 sections
TECENTRIQ HUMAN PRESCRIPTION DRUG LABEL 1 50242-918 INJECTION, SOLUTION 840 mg INTRAVENOUS BLA 29 sections